The PI3K/Akt/mTOR pathway: A potential pharmacological target in COVID-19.

Autor: Basile MS; IRCCS Centro Neurolesi Bonino Pulejo, C.da Casazza, 98124 Messina, Italy., Cavalli E; Department of Biomedical and Biotechnological Sciences, University of Catania, 95123 Catania, Italy., McCubrey J; Department of Microbiology and Immunology, Brody Medical Sciences Building, East Carolina University, Greenville, NC 27834, USA., Hernández-Bello J; Instituto de Investigación en Ciencias Biomédicas, Centro Universitario de Ciencias de la Salud Universidad de Guadalajara, 44340 Guadalajara, Mexico., Muñoz-Valle JF; University Center for Health Science, Department of Molecular Biology and Genomics, University of Guadalajara, Jalisco 49000, Mexico., Fagone P; Department of Biomedical and Biotechnological Sciences, University of Catania, 95123 Catania, Italy., Nicoletti F; Department of Biomedical and Biotechnological Sciences, University of Catania, 95123 Catania, Italy. Electronic address: ferdinic@unict.it.
Jazyk: angličtina
Zdroj: Drug discovery today [Drug Discov Today] 2022 Mar; Vol. 27 (3), pp. 848-856. Date of Electronic Publication: 2021 Nov 08.
DOI: 10.1016/j.drudis.2021.11.002
Abstrakt: Coronavirus disease 2019 (COVID-19) has emerged as a serious threat to global health. The disregulation of the phosphatidylinositol 3-kinase/protein kinase B/mammalian target of rapamycin (PI3K/Akt/mTOR) cell signaling pathway observed in patients with COVID-19 has attracted attention for the possible use of specific inhibitors of this pathway for the treatment of the disease. Here, we review emerging data on the involvement of the PI3K/Akt/mTOR pathway in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and the clinical studies investigating its tailored inhibition in COVID-19. Current in silico, in vitro, and in vivo data convergently support a role for the PI3K/Akt/mTOR pathway in COVID-19 and suggest the use of specific inhibitors of this pathway that, by a combined mechanism entailing downregulation of excessive inflammatory reactions, cell protection, and antiviral effects, could ameliorate the course of COVID-19.
Competing Interests: Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
(Copyright © 2021 Elsevier Ltd. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: